POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES IN LAST 24 HOURS (10.21.2021, 6:07pm CEST, WHO):   U.S. 75,267    India 18,454    Brazil 12,969    United Kingdom 48,545    Russia 36,339    Turkey 29,760    France 5,922    Iran 11,770    Argentina 1,303    Spain 1,235    Italy 3,699    Germany 16,077    Mexico 4,220    Poland 5,592    Philippines 3,656    Ukraine 22,415    Malaysia 5,516    Netherlands 4,609    Iraq 1,388    Thailand 9,727    Czechia 3,276    Canada 2,275    Chile 1,228    Romania 16,110    Israel 1,021    Serbia 7,745    Kazakhstan 1,995    Cuba 1,550    Vietnam 3,646    Jordan 1,232    Hungary 2,361    Austria 3,865    Greece 3,252    Georgia 4,411    Belarus 2,076    Bulgaria 4,522    Azerbaijan 2,303    Slovakia 3,091    Croatia 3,053    Ireland 2,147    Venezuela 1,162    Lithuania 3,349    Denmark 1,127    South Korea 1,441    Moldova 2,068    Slovenia 2,145    Armenia 2,603    Latvia 2,935    Estonia 1,505    China 29    Singapore 3,862    New Zealand 104    Australia 2,150   

Azerbaijan to conduct world’s first clinical trials of Sputnik V and AstraZeneca combination

Christian Fernsby |
The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces that the Ministry of Health of the Republic of Azerbaijan has issued a permit on February 8 to conduct clinical trials in the country of a combined use of Sputnik V and the vaccine developed jointly by AstraZeneca and Oxford University.

Article continues below



Topics: AZERBAIJAN   

Clinical trials will begin till the end of February.

RDIF, The Gamaleya Center, AstraZeneca and R-Pharm had earlier signed a Memorandum of Intent aimed at cooperation in vaccine development, which was announced in December 2020 during a meeting with Russian President Vladimir Putin.

The world’s first combined vaccine use will be conducted in line with clinical trials protocol registered on December 24, 2020.

The study will allow evaluating the immunogenicity and safety of the combined use of Sputnik V and the vaccine jointly developed by AstraZeneca and Oxford University. The research will be carried out over the course of six months in several countries with 100 volunteers recruited in each.


What to read next

World-first COVID-19 alternating dose vaccine study launches in UK
Russia's coronavirus vaccine Sputnik V to undergo trial in India
Russia approves Sputnik V vaccine use for people over 60